Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein

Nature Biotechnology

Volumn 27, Issue 6, 2009, Pages 567-571

  Eguchi, Akiko ^a,b,c   Meade, Bryan R ^a,b   Chang, Yung Chi ^d   Fredrickson, Craig T ^b   Willert, Karl ^b   Puri, Nitin ^e   Dowdy, Steven F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Life Technologies Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIONIC CHARGE; BINDING DOMAIN; CELLULAR UPTAKE; DOUBLE-STRANDED RNA; FUSION PROTEINS; GENE SILENCING; HUMAN EMBRYONIC STEM CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; INNATE IMMUNE RESPONSE; NEGATIVE CHARGE; PEPTIDE TRANSDUCTION; PRIMARY CELLS; RNA INTERFERENCE; SHORT INTERFERING RNA (SIRNA); SIRNA DELIVERY; T CELLS; TRANSCRIPTIONAL CHANGES;

AMINES; BACTERIOPHAGES; CELL MEMBRANES; CYTOTOXICITY; GENETIC ENGINEERING; NUCLEIC ACIDS; RNA;

ENDOTHELIAL CELLS;

DOUBLE STRANDED RNA; HYBRID PROTEIN; PEPTIDE TRANSDUCTION DOMAIN DOUBLE STRANDED RNA BINDING DOMAIN FUSION PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; EMBRYONIC STEM CELL; ENDOTHELIUM CELL; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; INNATE IMMUNITY; LUNG CARCINOMA; PRIORITY JOURNAL; RNA BINDING; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; UMBILICAL VEIN;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; EMBRYONIC STEM CELLS; EPITHELIAL CELLS; FLOW CYTOMETRY; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; GREEN FLUORESCENT PROTEINS; HUMANS; JURKAT CELLS; LUMINESCENT PROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; T-LYMPHOCYTES; UMBILICAL VEINS;

EID: 67149093390     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1541     Document Type: Article

References (20)

1. de Fougerolles, A., Vornlocher, H.P., Maraganore, J. & Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6, 443-453 (2007).
2. Kim, D.H. & Rossi, J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8, 173-184 (2007).
3. Bumcrot, D., Manoharan, M., Koteliansky, V. & Sah, D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2, 711-719 (2006).
4. Whitehead, K.A., Langer, R. & Anderson, D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129-138 (2009).
5. Behlke, M.A. Chemical modification of siRNAs for in vivo use. Oligonucleotides 18, 305-320 (2008).
6. Gump, J.M. & Dowdy, S.F. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol. Med. 13, 443-448 (2007).
7. Nakase, I. et al. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol. Ther. 10, 1011-1022 (2004).
8. Wadia, J.S., Stan, R.V. & Dowdy, S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10, 310-315 (2004).
9. Turner, J.J. et al. RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol. Dis. 38, 1-7 (2007).
10. Meade, B.R. & Dowdy, S.F. Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv. Drug Deliv. Rev. 60, 530-536 (2008).
11. Bevilacqua, P.C. & Cech, T.R. Minor-groove recognition of double-stranded RNA by the double-stranded RNA-binding domain from the RNA-activated protein kinase PKR. Biochemistry 35, 9983-9994 (1996).
12. Tian, B., Bevilacqua, P.C., Diegelman-Parente, A. & Mathews, M.B. The double-stranded-RNA-binding motif: interference and much more. Nat. Rev. Mol. Cell Biol. 5, 1013-1023 (2004).
13. Ryter, J.M. & Schultz, S.C. Molecular basis of double-stranded RNA-protein interactions: structure of a dsRNA-binding domain complexed with dsRNA. EMBO J. 17, 7505-7513 (1998).
14. Boyer, L.A. et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122, 947-956 (2005).
15. Henderson, J.K. et al. Preimplantation human embryos and embryonic stem cells show comparable expression of stage-specific embryonic antigens. Stem Cells 20, 329-337 (2002).
16. Hay, D.C., Sutherland, L., Clark, J. & Burdon, T. Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. Stem Cells 22, 225-235 (2004).
17. Zhang, W. et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat. Med. 11, 56-62 (2005).
18. Judge, A.D. et al. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494-505 (2006).
19. Safran, M. et al. Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol. Imaging 2, 297-302 (2003).
20. Miyoshi, H. et al. Development of a self-inactivating lentivirus vector. J. Virol. 72, 8150-8157 (1998).